Volume 27, Number 7—July 2021
Research
Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1
Table 4
Clinical characteristics of 17 children who failed 4 rounds of triclabendazole treatment for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru*
Child | Community | District | Age, y/sex | Other parasites | HAZ | Living under US $3.75/day | ERR, %† | Total drug dose, mg/kg‡ | Additional treatment received |
---|---|---|---|---|---|---|---|---|---|
1 | Anta | Anta | 6.8/F | Yes | −0.6 | 25 | 0§ | 90 | 1 more round |
2 | Anta | Anta | 14.1/M | No | −2.3 | 25 | 40 | 90 | 2 more rounds |
3 | Conchacalla | Anta | 10.5/M | No | −1.8 | 13 | 67 | 210 | Nitazoxanide |
4 | Conchacalla | Anta | 3.2/F | No | −2.4 | 36 | 40 | 50 | 2 more rounds |
5 | Conchacalla | Anta | 6.0/F | No | −0.4 | 36 | 0§ | 210 | None |
6 | Inquilpata | Anta | 8.5/M | No | −0.9 | 36 | 30 | 50 | 2 more rounds |
7 | Inquilpata | Anta | 9.7/F | No | −1.2 | 36 | 43 | 50 | 2 more rounds |
8 | Inquilpata | Anta | 3.3/M | Yes | −1.2 | 49 | +275 | 210 | None |
9 | Izcuchaca | Anta | 13.9/F | No | −0.6 | 36 | +574 | 150 | 1 more round |
10 | Izcuchaca | Anta | 7.4/M | No | −0.6 | 25 | 63 | 150 | 1 more round |
11 | Mantoclla | Anta | 7.3/F | Yes | −2.0 | 25 | 10 | 150 | None |
12 | Mantoclla | Anta | 9.2/F | Yes | −1.9 | 25 | 31 | 150 | None |
13 | Caccahuara | Ancahuasi | 13.1/F | No | −1.5 | 25 | 17 | 210 | Nitazoxanide |
14 | Caccahuara | Ancahuasi | 15.5/F | No | −1.9 | 13 | +50 | 210 | None |
15 | Caccahuara | Ancahuasi | 7.8/M | No | −1.1 | 25 | +100 | 210 | Nitazoxanide |
16 | Chaquillccasa | Ancahuasi | 11.5/M | Yes | −0.9 | 25 | +250 | 210 | None |
17 | Chaquillccasa | Ancahuasi | 5.5/F | Yes | −2.1 | 49 | 63 | 210 | 1 more round |
*ERR, egg reduction rate; HAZ, height-for-age Z score. †Between baseline and after the fourth round of treatment, as estimated by the number of eggs in Kato Katz tests. + signs indicate the percent increase in the egg count. ‡Total cumulative dose received after the fourth round of treatment §Diagnosed only by Lumbreras rapid sedimentation test and a negative Kato Katz test result.
1Preliminary results from this study were presented at the 68th Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 20‒24, 2019, National Harbor, MD, USA.
Page created: April 26, 2021
Page updated: June 16, 2021
Page reviewed: June 16, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.